Showing 61 to 68 of 68 results
GLP-1 Weight Loss Drugs May Reduce Breast Cancer Treatment Efficacy
A study of hundreds of women with triple-negative breast cancer found that those taking GLP-1 weight-loss drugs like Ozempic and Wegovy had significantly lower remission rates (28% vs 63%) after treatment, suggesting interference with chemotherapy and immunotherapy effectiveness.
GLP-1 Weight Loss Drugs May Reduce Breast Cancer Treatment Efficacy
A study of hundreds of women with triple-negative breast cancer found that those taking GLP-1 weight-loss drugs like Ozempic and Wegovy had significantly lower remission rates (28% vs 63%) after treatment, suggesting interference with chemotherapy and immunotherapy effectiveness.
Progress
52% Bias Score
High-Protein Bar David Capitalizes on Ozempic Trend
Peter Rahal, after selling RxBar for $600 million, launched a new high-protein bar called David, which sold over 1 million units in its first six weeks, driven by increased demand from users of weight-loss drugs like Ozempic.
High-Protein Bar David Capitalizes on Ozempic Trend
Peter Rahal, after selling RxBar for $600 million, launched a new high-protein bar called David, which sold over 1 million units in its first six weeks, driven by increased demand from users of weight-loss drugs like Ozempic.
Progress
44% Bias Score
Zepbound Outperforms Wegovy in 72-Week Weight Loss Trial
A new, yet un-peer-reviewed study shows Eli Lilly's Zepbound (tirzepatide) enabled 20% weight loss in 72 weeks among 751 obese or overweight participants, exceeding Wegovy's (semaglutide) under 14% weight loss; this translates to approximately 50 pounds lost with Zepbound versus 33 pounds with Wegov...
Zepbound Outperforms Wegovy in 72-Week Weight Loss Trial
A new, yet un-peer-reviewed study shows Eli Lilly's Zepbound (tirzepatide) enabled 20% weight loss in 72 weeks among 751 obese or overweight participants, exceeding Wegovy's (semaglutide) under 14% weight loss; this translates to approximately 50 pounds lost with Zepbound versus 33 pounds with Wegov...
Progress
40% Bias Score
Weight-Loss Drugs: Successes and Side Effects
This article examines the experiences of three individuals who used GLP-1 receptor agonist medications for weight loss, highlighting both the positive and negative aspects of these drugs.
Weight-Loss Drugs: Successes and Side Effects
This article examines the experiences of three individuals who used GLP-1 receptor agonist medications for weight loss, highlighting both the positive and negative aspects of these drugs.
Progress
24% Bias Score
France Approves Wegovy Reimbursement for Severely Obese Adults
France's Haute Autorité de Santé (HAS) approved Wegovy reimbursement for severely obese adults (BMI ≥35 kg/m²), following new data demonstrating reduced cardiovascular risks and approximately 17% weight loss; the drug, costing €274–€365 monthly, necessitates combined use with diet and exercise.
France Approves Wegovy Reimbursement for Severely Obese Adults
France's Haute Autorité de Santé (HAS) approved Wegovy reimbursement for severely obese adults (BMI ≥35 kg/m²), following new data demonstrating reduced cardiovascular risks and approximately 17% weight loss; the drug, costing €274–€365 monthly, necessitates combined use with diet and exercise.
Progress
36% Bias Score
Zepbound Shows 47% Greater Weight Loss Than Wegovy in Obesity Trial
A clinical trial showed that adults using the obesity drug Zepbound lost 47% more weight on average than those using Wegovy after 18 months, achieving an average weight loss of 50 pounds compared to 33 pounds, respectively.
Zepbound Shows 47% Greater Weight Loss Than Wegovy in Obesity Trial
A clinical trial showed that adults using the obesity drug Zepbound lost 47% more weight on average than those using Wegovy after 18 months, achieving an average weight loss of 50 pounds compared to 33 pounds, respectively.
Progress
48% Bias Score
US to Subsidize Obesity Medications for Millions
The US will spend $35 billion over 10 years to subsidize Wegovy and Mounjaro for millions of Americans with a BMI of 30 or higher, aiming to reduce obesity-related healthcare costs.
US to Subsidize Obesity Medications for Millions
The US will spend $35 billion over 10 years to subsidize Wegovy and Mounjaro for millions of Americans with a BMI of 30 or higher, aiming to reduce obesity-related healthcare costs.
Progress
40% Bias Score
Wegovy Launches in China
The weight-loss drug Wegovy launches in China, offering a potentially effective treatment for the country's large obese population, but also raising questions about affordability and healthcare systems.
Wegovy Launches in China
The weight-loss drug Wegovy launches in China, offering a potentially effective treatment for the country's large obese population, but also raising questions about affordability and healthcare systems.
Progress
40% Bias Score
Showing 61 to 68 of 68 results